Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NAT-ADAPT

Financiado

Understanding and harnessing natural variation in adaptability

The rise of antimicrobial resistance is an urgent global threat to human health and global healthcare capacities. Despite ongoing efforts to develop new antimicrobial drugs, eventual adaptation is an inevitable corollary of evolut... ver más

28/02/2026

CNRS

196K€

Presupuesto del proyecto: 196K€

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-24

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100%

2 Participantes

CNRS

195.91K€ | Lider

UGOT - GOETEBORGS UNIVERSITE...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PLAS-FIGHTER Exploiting plasmid–bacteria interactions to fight the evolut... 2M€ Cerrado

PCI2021-122024-2A NOVEL INTERVENTIONS FOR ELIMINATING ONE-HEALTH MOBILE ANTIMI... 44K€ Cerrado

PCI2021-122062-2A NOVEL INTERVENTIONS FOR ELIMINATING ONE-HEALTH MOBILE ANTIMI... 215K€ Cerrado

AGL2016-75536-P EVALUACION DE LOS BACTERIOFAGOS EN LA TRANSFERENCIA DE GENES... 203K€ Cerrado

HGTCODONUSE The evolutionary significance of synonymous variations Can... 2M€ Cerrado

COMBACTE-NET Combatting Bacterial Resistance in Europe 221M€ Cerrado

Duración del proyecto: 34 meses Fecha Inicio: 2023-04-24
Fecha Fin: 2026-02-28

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 196K€

Descripción del proyecto The rise of antimicrobial resistance is an urgent global threat to human health and global healthcare capacities. Despite ongoing efforts to develop new antimicrobial drugs, eventual adaptation is an inevitable corollary of evolution. Long-term solutions therefore require innovative approaches, including (1) learning to predict adaptation and (2) developing platforms to screen strategies against microbial adaptation. The capacity of an organism to adapt to new environments, also described as adaptability, is a heritable trait that varies substantially between even closely related lineages. Dissecting the genetic basis and mechanisms driving variation in adaptability is the critical first step in achieving these long-term objectives. As an MCSA fellow, Dr Xanita Saayman will receive training from Dr Gianni Liti at the Institute for Research in Cancer and Ageing (IRCAN) and from Dr Jonas Warringer during a secondment to the University of Gothenburg. Throughout NAT-ADAPT, Dr Saayman will exploit an extensive collection of Saccharomyces cerevisiae isolates with unprecedented scales of phenotypic and genotypic diversity. Bridging interdisciplinary fields (e.g., population genetics, phenomics, genomics, genome engineering), NAT-ADAPT will identify and characterise genetic drivers of adaptability, harnessing this knowledge for two applications. First, NAT-ADAPT will model adaptation dynamics based on quantifiable genome properties, serving as an invaluable resource for predicting the emergence of antimicrobial resistance. Second, NAT-ADAPT will produce ‘hyper-evolver’ Saccharomyces cerevisiae strains. Such strains can serve as critical platforms with which to screen strategies against microbial adaptation, improving the efficacy of current antimicrobial solutions.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores